KT-474

Sanofi's Dupixent achieved over $13 billion in global sales, establishing it as a gold standard in atopic dermatitis (AD) treatment.

Kymera Therapeutics is progressing KT-621, a STAT6 degrader, with Phase 1 data expected in Q2 2025 and Phase 1b trials in atopic dermatitis planned for Q2 2025.

KT-474, a novel small molecule, selectively inhibits MyD88, a key signaling protein in inflammatory pathways, offering a potential new approach to treating immune-mediated diseases.

Kymera Therapeutics reported $10.3 million in revenue, primarily from its collaboration with Sanofi, and holds a strong cash balance of $745 million, expected to last into the first half of 2027.